Mangoceuticals (MGRX) Capital Expenditures (2023)
Mangoceuticals (MGRX) reported Capital Expenditures of $3519.0 for Q1 2023.
Mangoceuticals (MGRX) Capital Expenditures (2023) Analysis & Trends
Mangoceuticals (MGRX) has 1 years of Capital Expenditures data on file, last reported at $3519.0 in Q1 2023.
- For the quarter ending Q1 2023, Capital Expenditures changed N/A year-over-year to $3519.0; the trailing twelve-month figure through Dec 2023 stood at $3519.0 (changed N/A YoY), and the FY2023 full-year result was $3519.0, changed N/A from the prior year.
- Capital Expenditures steadied at $3519.0 in Q1 2023.
- In the past five years, Capital Expenditures ranged from a high of $3519.0 in Q1 2023 to a low of $3519.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Veeva Systems | 31.81 Bn | 24.49 Bn | 662.02 Mn | 1.75 Mn |
| 2 | BrightSpring Health Services | 14.76 Bn | 13.86 Bn | 482.22 Mn | 21.54 Mn |
| 3 | Healthequity | 8.36 Bn | 8.10 Bn | 256.31 Mn | 15.93 Mn |
| 4 | Hinge Health | 5.91 Bn | 5.60 Bn | 154.23 Mn | 83,000.00 |
| 5 | 10x Genomics | 5.89 Bn | 5.35 Bn | 106.18 Mn | 118,000.00 |
| 6 | MiniMed | 4.45 Bn | 4.16 Bn | 480.00 Mn | 56.00 Mn |
| 7 | Waystar Holding | 4.41 Bn | 4.35 Bn | 216.84 Mn | 15.33 Mn |
| 8 | Doximity | 3.93 Bn | 3.18 Bn | 125.97 Mn | -6.65 Mn |
| 9 | Privia Health | 3.10 Bn | 2.68 Bn | - | -978,000.00 |
| 10 | Mangoceuticals | 9.39 Mn | 9.20 Mn | 29,001.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 3,519.00 |
| Mar 31, 2023 | 3,519.00 |